MAP3K6

Across TCGA pan-cancer cohorts, MAP3K6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP3K6 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP3K6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where MAP3K6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.181	0.421	.002	47	view →
HNSC	OS	Tertile	All	0.902	0.756	.009	18	view →
GBM	DFS	Quartile	All	0.274	0.481	.022	6	view →
CCRCC	OS	Median	All	0.902	0.772	.024	2	view →
LUAD	OS	Median	II,III,IV	0.519	0.766	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP3K6–PDAC (DFS)

Open the PDAC breakdown →